GlaxoSmithKline (NYSE:GSK) and drug partner Human Genome Sciences (NASDAQ:HGSI) have started clinical trials on a different version of lupus drug Benlysta that would be easier to administer to patients. Benlysta is currently administered by intravenous infusion. The companies have started a phase 3 clinical trial to test a once-a-week injectable version of the drug. Studies […]
A Cleveland Clinic researcher has received a $1.1 million grant from the U.S. Department of Defense to study why lupus is so much more prevalent in females than males. Trine Jorgensen, a researcher in the Clinic’s Department of Immunology, was one of two researchers nationally to receive a DoD grant for lupus research, according to […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A Philadelphia-area pharmaceutical company developing innovative treatments for bone disorders has raised fresh capital, likely working toward the commercialization of an osteoporosis treatment. Zelos Therapeutics has raised $2.8 million, according to a recent filing with the Securities and Exchange Commission. President and CEO Brian MacDonald was not available to comment on the fund-raise. The company’s […]
It’s been five months since new lupus drug Benlysta became the first new U.S. Food and Drug Administration-approved lupus treatment in 56 years. Since receiving FDA approval, GlaxoSmithKline (NYSE:GSK) and drug partner Human Genome Sciences (NASDAQ:HGSI) have been working to build the drug’s sales in the United States while also seeking approval in additional markets. […]
Immunotherapy company Argos Therapeutics plans to start enrolling patients in a phase 3 kidney cancer trial for its lead candidate in the fourth quarter. But first, Argos needs money. The company has just over $3 million in cash on hand, according to securities documents. The Durham, North Carolina company on July 29 filed plans to […]
Lupus drug Benlysta is two-for-two this week. GlaxoSmithKline (NYSE:GSK) and drug partner Human Genome Sciences (NASDAQ:HGSI) said Thursday that the European Commission has granted marketing authorization for Benlysta, an announcement that comes just days after Canada’s regulators approved the drug. “The European approval of Benlysta represents a significant milestone, and we are very pleased to […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Lupus drug Benlysta, developed by GlaxoSmithKline (NYSE:GSK) and drug partner Human Genome Sciences (NASDAQ:HGSI), can now count Canada among the markets where it will offer the first new lupus treatment in nearly 50 years. The companies on Tuesday announced that Health Canada has approved Benlysta. People with lupus in Canada can expect to see the […]
LabCorp‘s (NYSE:LH) deadline to buy DNA testing services firm Orchid Cellmark (NASDAQ:ORCH) has been extended to July 15, the third extension for the deal in the last month. The Burlington, North Carolina-based diagnostics and laboratory services company in April had announced a definitive agreement to buy Orchid in a deal valued at more than $85 million. […]
BioCryst Pharmaceuticals CEO Jon Stonehouse got a jump on Memorial Day weekend travel. Today, Stonehouse is in London where he will tell European doctors and healthcare professionals how BioCryst’s experimental gout drug can pair with a nearly 50-year-old gout treatment and make it work significantly better. Stonehouse is presenting at the Annual European Congress of […]
Among the life science current events from last week: NIH grant rankings, lessons from GSK's Benlysta lupus drug breakthrough, Medtronic's battle with GPOs, the self-creation of a urethra, and debates over the value of an Ohio local investment group.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The lupus drug Benlysta is a perfect example of the new blockbuster drug: expensive products targeting ever more specific segments of the patient population. And as GSK and other pharmaceutical companies continue working on biologics, expect more of this to come. Years before Benlysta’s approval as the first new lupus treatment in more than 50 years, GSK signed a development and commercialization agreement with Human Genome Sciences in which the two companies would share equally in the costs and net proceeds that come from it.
Lupus drug Benlysta has been approved by the Food and Drug Administration becoming the first new lupus drug approved in 56 years. The intravenous drug was developed by Maryland-based Human Genome Sciences and GlaxoSmithKline.
Tuberculosis, diabetes and lupus are among the diseases targeted by Aarden Pharmaceuticals, based in Indiana. The company's technology inhibits protein tyrosine phosphatases, a step which scientists have long believed will unlock new treatments for an array of ailments.
Doctors from Akron Children's Hospital will begin providing specialty pediatric care at MetroHealth System's main Cleveland campus in January. Akron Children's specialists will focus on the areas of pediatric cardiology, gastroenterology, cancer and blood disorders, and critical care.
The University of Minnesota has licensed a test for lupus to Laboratory Corporation of America Holdings (NYSE:LH). Developed by Emily Baechler Gillespie, an assistant professor of medicine at the university's medical school, the test can help doctors proactively treat symptoms of lupus, a painful autoimmune disease.